MXPA03010328A - Acidos hidroxinamicos y acil hidroxaminasas como inhibidores de naaladasa. - Google Patents

Acidos hidroxinamicos y acil hidroxaminasas como inhibidores de naaladasa.

Info

Publication number
MXPA03010328A
MXPA03010328A MXPA03010328A MXPA03010328A MXPA03010328A MX PA03010328 A MXPA03010328 A MX PA03010328A MX PA03010328 A MXPA03010328 A MX PA03010328A MX PA03010328 A MXPA03010328 A MX PA03010328A MX PA03010328 A MXPA03010328 A MX PA03010328A
Authority
MX
Mexico
Prior art keywords
hydroxamines
acyl
compounds
hydroxamic acids
naaladase inhibitors
Prior art date
Application number
MXPA03010328A
Other languages
English (en)
Inventor
Tsukamoto Takashi
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Publication of MXPA03010328A publication Critical patent/MXPA03010328A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invencion se refiere a compuestos novedosos, composiciones farmaceuticas y equipos diagnosticos que comprenden dichos compuestos, y metodos para usar dichos compuestos para inhibir la actividad de la enzima NAALADasa, detectar enfermedades en donde los niveles de NAALADasa estan alterados, afectar la actividad neuronal, afectar la actividad del TGF-(, inhibir la angiogenesis, y tratar anormalidades del glutamato, neuropatia, dolor, trastornos compulsivos, enfermedades de la prostata, canceres y glaucoma.
MXPA03010328A 2001-05-11 2002-05-10 Acidos hidroxinamicos y acil hidroxaminasas como inhibidores de naaladasa. MXPA03010328A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29001501P 2001-05-11 2001-05-11
US34274101P 2001-12-28 2001-12-28
PCT/US2002/014635 WO2002092553A1 (en) 2001-05-11 2002-05-10 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors

Publications (1)

Publication Number Publication Date
MXPA03010328A true MXPA03010328A (es) 2004-02-17

Family

ID=26965968

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010328A MXPA03010328A (es) 2001-05-11 2002-05-10 Acidos hidroxinamicos y acil hidroxaminasas como inhibidores de naaladasa.

Country Status (7)

Country Link
US (2) US6884907B2 (es)
EP (1) EP1392648A1 (es)
JP (1) JP4625236B2 (es)
AU (1) AU2002256505B2 (es)
CA (1) CA2446740A1 (es)
MX (1) MXPA03010328A (es)
WO (1) WO2002092553A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092273A2 (en) * 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
AU2002256505B2 (en) * 2001-05-11 2008-06-26 Eisai Inc. Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
US7148250B2 (en) 2001-12-28 2006-12-12 Guilford Pharmaceuticals Inc. Indoles as NAALADase inhibitors
JP4016667B2 (ja) * 2002-02-15 2007-12-05 ヤマハ株式会社 光ディスク装置、フォーカス制御方法およびプログラム
EP1988088A1 (en) * 2003-03-03 2008-11-05 Guilford Pharmaceuticals Inc. Thiolactones
US20040186081A1 (en) * 2003-03-03 2004-09-23 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating opioid tolerance
US20060004098A1 (en) * 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
RU2295517C1 (ru) * 2005-06-24 2007-03-20 Институт проблем химической физики РАН (ИПХФ РАН) Производные дикарбоновых кислот, ингибиторы метастазов и средства, повышающие химиотерапевтическую активность противоопухолевых препаратов, способ усиления эффективности цитостатиков, способ ингибирования процесса метастазирования
EP2209498A2 (en) 2007-10-03 2010-07-28 Cornell University Treatment of proliferative disorders using antibodies to psma
US20140081017A1 (en) * 2012-09-14 2014-03-20 Methylgene Inc. Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents
KR102625793B1 (ko) 2015-05-06 2024-01-15 얀센 바이오테크 인코포레이티드 전립선 특이적 막 항원 결합 피브로넥틴 iii형 도메인
US11059775B2 (en) 2016-11-18 2021-07-13 The Johns Hopkins University Prodrug compositions and utility of hydroxamate-based GCPII inhibitors
JP7219806B2 (ja) * 2019-03-28 2023-02-08 富士フイルム株式会社 薬液、被処理物の処理方法
WO2021155167A1 (en) * 2020-01-31 2021-08-05 The Johns Hopkins University Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282986A (en) 1960-10-06 1966-11-01 Merck & Co Inc N-acylated hydroxamic acids and derivatives thereof
OA07000A (fr) * 1981-01-23 1983-08-31 Shell Internatiole Research Mi Compositions fongicides.
JPH0592948A (ja) * 1991-02-06 1993-04-16 Yoshitomi Pharmaceut Ind Ltd プロピオン酸アミド誘導体およびその医薬用途
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
WO1994015908A1 (en) * 1993-01-14 1994-07-21 Yoshitomi Pharmaceutical Industries, Ltd. Propionamide derivative and medicinal use thereof
NZ288299A (en) 1994-06-22 1998-06-26 British Biotech Pharm Substituted (hetero)aryl-sulphonylaminomethyl-hydroxamic acid and medicaments
JP2829501B2 (ja) * 1994-11-04 1998-11-25 参天製薬株式会社 ヒドロキシ基を含有する新規１，３−ジアルキルウレア誘導体
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
EP0911319A1 (en) 1997-09-01 1999-04-28 Roche Diagnostics GmbH Malonic acid based matrix metalloproteinase inhibitors
CN1298299A (zh) * 1998-02-07 2001-06-06 英国生物技术药物有限公司 抗菌剂
US6458775B1 (en) * 1998-07-06 2002-10-01 Guilford Pharmaceutical Inc. NAALADase inhibitors useful as pharmaceutical compounds and compositions
US6313159B1 (en) * 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
AU2001265119A1 (en) * 2000-05-30 2001-12-11 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating amyotrophic lateral sclerosis
AU6661901A (en) 2000-05-30 2001-12-11 Guilford Pharm Inc Naaladase inhibitors for treating retinal disorders and glaucoma
WO2001092273A2 (en) 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
AU2002256505B2 (en) * 2001-05-11 2008-06-26 Eisai Inc. Hydroxamic acids and acyl hydroxamines as naaladase inhibitors

Also Published As

Publication number Publication date
JP4625236B2 (ja) 2011-02-02
WO2002092553A1 (en) 2002-11-21
EP1392648A1 (en) 2004-03-03
AU2002256505B2 (en) 2008-06-26
JP2004535398A (ja) 2004-11-25
CA2446740A1 (en) 2002-11-21
US20060009525A1 (en) 2006-01-12
US20030087897A1 (en) 2003-05-08
US6884907B2 (en) 2005-04-26

Similar Documents

Publication Publication Date Title
WO2003057670A3 (en) Indoles as naaladase inhibitors
WO2001092273A3 (en) Benzenedicarboxylic acid derivatives
MXPA03010328A (es) Acidos hidroxinamicos y acil hidroxaminasas como inhibidores de naaladasa.
CY1108893T1 (el) Παραγωγα θειοαλκυλ βενζοϊκου οξεος
WO2002057222A3 (en) Thiol-based naaladase inhibitors
ATE432923T1 (de) 5-aminoindenoä1,2-cüpyrazol-4-one als antitumor- und wachstumshemmende mittel
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
CA2337797A1 (en) Naaladase inhibitors useful as pharmaceutical compounds and compositions
BRPI0411275A (pt) compostos de carbonila como inibidores de histona deacetilase para tratamento de doenças; composição farmacêutica; método de modular a atividade catalìtica de hdac; método de tratar doença em um indivìduo; utilização de um composto ou composição; método de inibir hdac
AU2002363182A1 (en) Smad7 inhibitors for the treatment of cns diseases
WO2001034596A3 (en) Pyrrolecarbonylimino derivatives as naaladase inhibitors
DE69903618D1 (en) Phosphinsäure-derivate
WO2002062777A3 (en) Amino ceramide-like compounds and therapeutic methods of use
WO2001097794A3 (en) Inhibitors of matriptase for the treatment of cancer
MX9701820A (es) Compuestos de pirazolo [3,4-g] quinoxalina que inhiben proteina tirosina quinasa receptora de pdgf.
WO2003099202A3 (en) Beta-secretase inhibitors
MXPA04000531A (es) Acilsemicarbazidas como inhibidores de cinasa dependiente de ciclina utiles como agentes anti-cancer y anti-proliferativos.
IL172134A0 (en) Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
CY1109356T1 (el) Θειολακτονες ως αναστολεις της νααladασης
WO2003035048A3 (en) Methods for the treatment of osteoarthritis and compositions thereof
IL147953A0 (en) Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-carboxamide, having anti-epileptic, neurological, and cns activity, and method for their preparation
EP3982945A1 (en) Use of marimastat for preventing and/or treating epileptogenesis
ATE449089T1 (de) Aminoceramidartige verbindungen und therapeutische anwendungen
GEP20033130B (en) Inhibitors of IMPDH Enzyme

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
GB Transfer or rights
GB Transfer or rights